These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 12493802)

  • 1. Comparative spectrum and activity of NVP-PDF386 (VRC4887), a new peptide deformylase inhibitor.
    Jones RN; Rhomberg PR
    J Antimicrob Chemother; 2003 Jan; 51(1):157-61. PubMed ID: 12493802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of a new antibiotic, NVP-PDF386 (VRC4887), against Chlamydia pneumoniae.
    Roblin PM; Hammerschlag MR
    Antimicrob Agents Chemother; 2003 Apr; 47(4):1447-8. PubMed ID: 12654690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial spectrum and activity of NVP PDF-713, a novel peptide deformylase inhibitor, tested against 1,837 recent Gram-positive clinical isolates.
    Jones RN; Fritsche TR; Sader HS
    Diagn Microbiol Infect Dis; 2004 May; 49(1):63-5. PubMed ID: 15135503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates.
    Jones RN; Moet GJ; Sader HS; Fritsche TR
    J Antimicrob Chemother; 2004 May; 53(5):804-7. PubMed ID: 15056649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
    Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
    J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance.
    Fritsche TR; Sader HS; Cleeland R; Jones RN
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1468-76. PubMed ID: 15793128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci.
    Jones RN; Deshpande LM; Mutnick AH; Biedenbach DJ
    J Antimicrob Chemother; 2002 Dec; 50(6):915-32. PubMed ID: 12461013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality control guidelines for MIC susceptibility testing of NVP PDF-713: a novel peptide deformylase inhibitor.
    Anderegg TR; Biedenbach DJ; Jones RN;
    Int J Antimicrob Agents; 2003 Jul; 22(1):84-6. PubMed ID: 12842335
    [No Abstract]   [Full Text] [Related]  

  • 9. N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity.
    Hackbarth CJ; Chen DZ; Lewis JG; Clark K; Mangold JB; Cramer JA; Margolis PS; Wang W; Koehn J; Wu C; Lopez S; Withers G; Gu H; Dunn E; Kulathila R; Pan SH; Porter WL; Jacobs J; Trias J; Patel DV; Weidmann B; White RJ; Yuan Z
    Antimicrob Agents Chemother; 2002 Sep; 46(9):2752-64. PubMed ID: 12183225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria.
    Chamberland S; Blais J; Hoang M; Dinh C; Cotter D; Bond E; Gannon C; Park C; Malouin F; Dudley MN
    Antimicrob Agents Chemother; 2001 May; 45(5):1422-30. PubMed ID: 11302805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698.
    Lofland D; Difuntorum S; Waller A; Clements JM; Weaver MK; Karlowsky JA; Johnson K
    J Antimicrob Chemother; 2004 Apr; 53(4):664-8. PubMed ID: 14973152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activities of peptide deformylase inhibitors against gram-positive pathogens.
    Wise R; Andrews JM; Ashby J
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1117-8. PubMed ID: 11897602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries.
    Jones RN; Fritsche TR; Sader HS; Ross JE
    Diagn Microbiol Infect Dis; 2007 Oct; 59(2):199-209. PubMed ID: 17908617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
    Noviello S; Ianniello F; Leone S; Esposito S
    J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents.
    Apfel C; Banner DW; Bur D; Dietz M; Hirata T; Hubschwerlen C; Locher H; Page MG; Pirson W; Rossé G; Specklin JL
    J Med Chem; 2000 Jun; 43(12):2324-31. PubMed ID: 10882358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA.
    McCloskey L; Moore T; Niconovich N; Donald B; Broskey J; Jakielaszek C; Rittenhouse S; Coleman K
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():13-21. PubMed ID: 10824027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Commercial broth microdilution panel validation and reproducibility trials for NVP PDF-713 (LBM 415), a novel inhibitor of bacterial peptide deformylase.
    Fritsche TR; Moet GJ; Jones RN
    Clin Microbiol Infect; 2004 Sep; 10(9):857-60. PubMed ID: 15355422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations.
    Jones RN; Ross JE; Fritsche TR; Sader HS
    J Antimicrob Chemother; 2006 Feb; 57(2):279-87. PubMed ID: 16326811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In vitro activity of trovafloxacin in 238 respiratory pathogens].
    Alarcón T; Domingo D; Prieto N; Sánchez S; López-Brea M
    Rev Esp Quimioter; 1998 Mar; 11(1):47-51. PubMed ID: 9795289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) program: report of linezolid activity over 9 years (2004-12).
    Mendes RE; Hogan PA; Streit JM; Jones RN; Flamm RK
    J Antimicrob Chemother; 2014 Jun; 69(6):1582-8. PubMed ID: 24468866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.